Investor Area

Home / Investor Area / Company Snapshot

Company Snapshot

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). In June 2018 CLINUVEL submitted a new drug application with the US FDA seeking marketing authorisation for SCENESSE®. More information on EPP can be found at

Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore.

Download the CLINUVEL Investor Summary

Facts ASX Listed 2001
Shares on Issue 48,960,633
Conditional performance rights 647,913
52 week price range (26/08/2019) $11.86 – $39.85
Market cap (26/08/2019) A$1.23b
Locations Melbourne, Australia Company headquarters
Zug, Switzerland Swiss operational office
Leatherhead, UK UK operational office
Singapore Asian operational office
Stock listings ASX CUV
Xetra-DAX UR9
Key financial statistics FY June 2019 Total revenue A$32.5m
Net profit A$18.1m
Net cash increase A$17.2m
Cash A$54.3m
Total assets A$62.3m
Equity A$57.2m
Products SCENESSE® (afamelanotide 16mg implant) First-in-class photoprotective and repigmentation
drug with EMA approval for rare disease EPP, NDA submitted to US FDA. Phase IIb trial ongoing in
Singapore for vitiligo
CUV9900 Alpha-Melanocyte Stimulating Hormone
(alpha-MSH) analogues in early development
People Stan McLiesh Non-Executive Chair
Dr Philippe Wolgen CEO, Director
Brenda Shanahan Non-Executive Director
Willem Blijdorp Non-Executive Director
Dr Karen Agersborg Non-Executive Director
Dr Dennis Wright Acting Chief Scientific Officer
Darren Keamy CFO, Company Secretary

Last Updated: 28 August 2019